Skip to Content

Research & Funding

Past CIP InitiativesRSS

This page lists past opportunities from CIP.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • PAR-15-266: Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24)

    Source: FOA Page

    • Release Date: June 11, 2015
    • Application Receipt Date: Nov 17, 2015; Jun 14, 2016; Nov 17, 2016; June 14, 2017; Nov 17, 2017; Jun 14, 2018
    • Expiration Date: Jun 15, 2018
    • Contacts:

      Huiming Zhang, Ph.D., NCI, Phone: 240-276-5979, (zhanghui@mail.nih.gov)
      Cheryl L. Marks, Ph.D., NCI, Phone: 240-276-6217 (marksc@mail.nih.gov)
      Richard V. Mazurchuk, Ph.D., NCI, Phone: 240-276-7126 (mazurchukrv@mail.nih.gov)

    The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve correlation of results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations.

    Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients’ malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, , imaging platforms, QI methods, decision support software and informatics to populate the research resource. 

  • PAR-14-013: Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21) - Reissued

    • Release Date: March 05, 2014
    • Application Receipt Date: June 30, 2014; October 10, 2014; February 9, 2015, June 9, 2015; October 9, 2015; February 9, 2015; June 9, 2016; October 11, 2016; February 9, 2017, by 5:00 PM local time of applicant organization.
    • Expiration Date: February 10, 2017
    • Contacts: Imaging trials:
      Lori A. Henderson, Ph.D., NCI, Phone: 240-276-5930, (hendersonlori@mail.gov)
      Frank I. Lin, M.D., NCI, Phone: 240-276-5932, (frank.lin2@nih.gov)
      Image-Guided Intervention [IGI] trials:
      Keyvan Farahani, Ph.D., NCI, Phone: 240-276-5921, (farahank@mail.nih.gov)
      Radiation Therapy related trials:
      Bhadrasain Vikram, M.D., NCI, Phone: 240-276-5690, (vikramb@mail.nih.gov)

    This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network.

  • PAR-13-185: Image-guided Drug Delivery in Cancer (R01)

    • Release Date: May 14, 2013
    • Application Receipt Date: June 19, 2013; November 19, 2013; June 19, 2014; November 19, 2014; June 19, 2015; November 19, 2015
    • Expiration Date: November 20, 2015
    • Contacts:

      Contact: Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 240-276-5921

      Please see the FOA for a complete list of contacts.

    This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.

  • PAR-13-169: Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01)

    • Release Date: May 14, 2013
    • Application Receipt Date: Standard dates apply: see http://grants.nih.gov/grants/funding/submissionschedule.htm
    • Expiration Date: May 8, 2016
    • Contacts:

      Houston Baker, Ph.D.; Phone: 240-276-5908; Email: bakerhou@mail.nih.gov

      Please see the FOA for a complete list of contacts.

    This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators to accelerate the translation of either preclinical or clinical in vivo imaging systems and/or methods that are designed to solve a targeted cancer problem. The proposed imaging system/methods may include single or multi-modality in vivo imaging and spectroscopy systems, image-guided and drug delivery systems, image analysis, and related research resources. This FOA may also include, as a secondary goal, support for other laboratory imaging or reference methods as required to validate the performance of the proposed in vivo imaging system and/or methods. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate the following examples, among others: (a) current commercially supported imaging systems/methods, (b) next-generation imaging systems/methods, (c) quality assurance and quality control methods, (d) validation and correlation studies, (e) quantitative imaging methods, and (f) related research resources. Because appropriate applications must be translational in scope, this FOA defines innovation as a coherent translational plan to deliver emerging or new capabilities for preclinical or clinical use that are not yet broadly employed in preclinical or clinical settings. The partnerships on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate their proposed imaging system/methods to solve a targeted cancer problem. This FOA will support clinical trials that emphasize optimization and validation of the performance of imaging systems, including devices, agents and/or methods. This FOA will not support commercial production, or basic research projects that do not emphasize translational development and optimization of the methods for a targeted cancer problem.

  • PAR-11-216: Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21)

    • Release Date: May 24, 2011
    • Application Receipt Date: See below
    • Expiration Date: March 14, 2014
    • Contacts:

      Imaging trials:

      Lalitha K. Shankar, M.D., Ph.D., NCI, Phone: 240-276-6510, (shankarl@mail.nih.gov)
      Frank I. Lin, M.D., NCI, Phone: 240-276-5932, (frank.lin2@nih.gov)

      Image-Guided Intervention trials:

      Keyvan Farahani, Ph.D., NCI, Phone: 240-276-5921, (farahank@mail.nih.gov)

      Radiation Therapy trials:

      Bhadrasain Vikram, M.D., NCI, Phone: 240-276-5690, (vikramb@mail.nih.gov)

    • Application Receipt/Submission Date(s): July 27, 2011; November 10, 2011; March 13, 2012; July 11, 2012; November 13, 2012; March 13, 2013; July 11, 2013; November 13, 2013; March 13, 2014, by 5:00 PM local time of applicant organization.

    This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. The imaging and Image-guided Intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Center and/or Cooperative Groups.

    See full description in NIH Guide: PAR-11-216;

  • PAR-11-150: Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01)

    • Release Date: March 14, 2011
    • Application Receipt Date: Standard dates
    • Expiration Date: May 8, 2014
    • Contacts:

      Robert J. Nordstrom, Ph.D. (nordstrr@mail.nih.gov) at 240-276-5934

    The Cancer Imaging Program, (NCI), solicits applications to promote research on quantitative imaging of tumor response to cancer therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. Proposed projects should include the appropriate development and adaptation/implementation of quantitative imaging methods, protocols and software solutions/tools (using existing commercial imaging platforms and instrumentation), and their application in current and planned Phase 1-2 clinical therapy trials. No support for the clinical trials, as such, will be provided under this initiative. The proposed projects must focus on imaging-derived quantitative measurements of responses to drugs and/or radiation therapy, and/or image-guided interventions. It is anticipated that these research goals will require multidisciplinary efforts. Therefore, this announcement solicits applications from multi-disciplinary teams to include oncologists as well as clinical and basic imaging scientists. The involvement of industrial partners in the development of the quantitative imaging methods is not required, but is strongly encouraged. Awardees form a Quantitative Imaging Network (QIN) to share ideas and approaches to validate and standardize imaging data and related imaging meta-data for quantitative measurements of responses to cancer therapies.

    See the CIP QIN website for a description of the program.

    • No set-aside

    See full description in NIH Guide: PAR-11-150

    Clarification of Scope and Requirements of PAR-11-150: NOT-CA-11-011

  • PA-10-080 and PA-10-079: Image-Guided Interventions (STTR [R41/R42] & SBIR [R43/R44])

    • Release Date: January 08, 2010
    • Application Receipt Date: Multiple dates, see announcements.
    • Expiration Date: January 8, 2013
    • Contacts:

      David Beylin, M.S., NCI, Phone: 301-496-0079, Email: beylind@mail.nih.gov
      Expires January 8, 2013

    These Funding Opportunity Announcements (FOA) support the development and clinical validation of systems for image-guided interventions (IGIs) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; the validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multisite clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals..

    See full description in NIH Guide: STTR (R41/R42) PA-10-080; SBIR (R43/44) PA-10-079

  • PA-09-253: Image-guided Drug Delivery in Cancer (R01)

    • Release Date: August 13, 2009
    • Application Receipt Date: Standard dates
    • Expiration Date: May 8, 2013
    • Contacts:

      Contact: Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 240-276-5921

    The NCI encourages innovative translational research in the development of quantitative in vivo imaging characterization of image-guided drug delivery (IGDD) in cancer, including characterizations of the target, delivery validation, and therapy response. This initiative will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer. Validation studies in non-human primates or large animal models and first in human studies directed towards translation of IGDD technology into the clinic will be considered appropriate for this initiative.

    • No set-aside

    See full description in NIH Guide: PA-09-253

  • PAR-09-157: In vivo Cellular and Molecular Imaging Centers (ICMICs) (P50)

    • Release Date: April 13, 2009
    • Application Receipt Date: October 28, 2009, October 28, 2010, October 28, 2011
    • Expiration Date: October 29, 2011
    • Contacts:

      Anne Menkens, Ph.D. (am187k@nih.gov) at 301-496-9531

    The Cancer Imaging Program, and the Division of Cancer Diagnosis and Treatment, at the National Cancer Institute (NCI), invite new or renewal (competing) applications for P50 Research Center Grants for In vivo Cellular and Molecular Imaging Centers (ICMICs). The program will fund the 5-year P50 ICMIC grants to support interdisciplinary scientific teams conducting cutting-edge cancer molecular imaging research. ICMIC funding is designed to: (1) support innovative cancer molecular imaging research projects; (2) support unique core facilities; (3) enable the awardees to initiate pilot research in new promising directions; and (4) provide interdisciplinary career development opportunities for investigators new to the field of molecular cancer imaging.

    • Letters of Intent Receipt Dates: September 28, 2009, September 28, 2010, September 28, 2011
    • No set-aside

    See full description in NIH Guide:PAR-09-157

  • PAR-08-225: Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01)

    • Release Date: August 03, 2008
    • Application Receipt Date: Standard dates
    • Expiration Date: May 8, 2011
    • Contacts:

      Robert J. Nordstrom,  Ph.D. (nordstrr@mail.nih.gov) at 301-594-9121

    The Cancer Imaging Program, (NCI), solicits applications to promote research on quantitative imaging of tumor response to cancer therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. Proposed projects should include the appropriate development and adaptation/implementation of quantitative imaging methods, protocols and software solutions/tools (using existing commercial imaging platforms and instrumentation), and their application in current and planned Phase 1-2 clinical therapy trials. No support for the clinical trials, as such, will be provided under this initiative. The proposed projects must focus on imaging-derived quantitative measurements of responses to drugs and/or radiation therapy, and/or image-guided interventions. It is anticipated that these research goals will require multidisciplinary efforts. Therefore, this announcement solicits applications from multi-disciplinary teams to include oncologists as well as clinical and basic imaging scientists. The involvement of industrial partners in the development of the quantitative imaging methods is not required, but is strongly encouraged. Awardees will form a Quantitative Imaging Network (QIN) to share ideas and approaches to validate and standardize imaging data and related imaging meta-data for quantitative measurements of responses to cancer therapies.

    • No set-aside

    See full description in NIH Guide: PAR-08-225